5/1/2013

Raptor Pharmaceutical obtained approval from the FDA to market Procysbi as a treatment for nephropathic cystinosis, a rare genetic disorder. The drug, a delayed-release formulation of cysteamine bitartrate, delays kidney and other damage by reducing cystine levels.

Full Story:
Reuters

Related Summaries